Close

SIAT® ADA Positive Control & Reagent Formation Service

Introduction Positive Control Selection for ADA Assay Service FAQ Resources

Immunogenicity refers to the trait of a drug that stimulates the body to form a line of antibodies or sensitized lymphocytes. Evaluation of immunogenicity in preclinical and clinical trials is an important part of biopharmaceuticals. Anti-drug antibodies (ADA) produced after administration may neutralize drug activity, affect drug clearance, plasma half-life, and tissue distribution, and alter pharmacodynamic (PD)/pharmacokinetic (PK) characteristics. Therefore, it is necessary to examine the immunogenicity when evaluating drug safety. Creative Biolabs owns state-of-the-art testing equipment and technology to provide you with the most accurate data on immunogenicity testing.

Clinical Impact of ADA Production

Importance of Positive Control Selection for ADA Assay

The ADA method may affect the test results and experimental data by potential interference during the measurement. In actual testing, the interference of this potential experimental data may result from the use of a proxy ADA when testing samples. The choice of an alternative positive control is challenging because no antibody can produce a positive response to all variants of ADA in preclinical studies. The affinity, specificity, and concentration of each antibody will vary. Corresponding in vivo polyclonal reactions can also result in multiple antibodies that react differently. Some of the positive controls used by the proxy ADA are antibodies that have been purified and can be used to stimulate normal serum to cause a positive QC peak in the expected ADA serum. Antibodies can be collected from purified antibodies, or hyperimmune animals and preclinical or clinical trials. From the hyperimmune serum, the ADA positive serum can be identified.

What Can We Do?

Fig. 1 A schematic image of bridging immunoassay. Fig. 1 Bridging immunoassay.1

The generation of antibody class diversity requires not only a combination of multiple analytical methods and platform technologies, but also an increasing demand for the development and validation of accurate and robust bioanalytical methods, and requires that the resulting data stand up to regulatory review. Creative Biolabs owns comprehensive technical information and experimental experience. Please contact us as soon as possible for more information and we will be glad to serve you.

Other optional SIAT® Anti-drug Antibodies (ADA) Assays:

Reference
  1. Nath, Nidhi, et al. "Development of NanoLuc bridging immunoassay for detection of anti-drug antibodies." Journal of Immunological Methods 450 (2017): 17-26. Distributed under Open Access license CC BY 4.0, without modification.

FAQ

  1. What is a positive control in an ADA assay?

    A positive control in an ADA assay is a sample known to contain antibodies against the drug being tested. It is used to demonstrate that the assay is functioning correctly and can detect ADAs if they are present. Positive controls help ensure the reliability and consistency of assay results across different runs and laboratories.

  2. How is a positive control for an ADA assay generated?

    Positive controls for ADA assays are typically generated by immunizing animals (like rabbits or goats) with the therapeutic protein or by isolating antibodies from patients who have developed ADAs. These antibodies are then purified and characterized to ensure their suitability as controls in terms of specificity and reactivity.

  3. What characteristics should a positive control have for an ADA assay?

    A positive control should be highly specific to the drug, with a well-defined affinity and concentration that consistently yields detectable and reproducible results within the assay's dynamic range. It should not cross-react with other components in the assay or with irrelevant targets to avoid false positives.

  4. Can human-derived antibodies be used as positive controls?

    Human-derived antibodies can be used as positive controls, especially when they are available from patients who have developed ADAs against the therapeutic drug. These antibodies are particularly valuable as they closely represent the human immune response to the drug, providing a realistic assessment of the assay's performance.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

VideosArticles

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us